Acacetin-Mediated MAPK1/HMOX1 Axis: A New Target in Intervertebral Disc Degeneration

Study Background and Research Question

Intervertebral disc degeneration (IVDD) is a principal cause of chronic low back pain and disability worldwide, characterized by the loss of function and viability of nucleus pulposus cells (NPCs). Current therapeutic strategies, such as anti-inflammatory drugs and surgical interventions, focus mainly on symptom management rather than disease modification. A major challenge in this field is the incomplete understanding of the molecular mechanisms that drive NPC dysfunction, particularly the roles of regulated cell death pathways such as pyroptosis and selective mitochondrial autophagy (mitophagy) in IVDD progression. The reference study (Yu et al., 2025) aims to identify new mechanisms and potential therapeutic targets by investigating the effect of Duhuo Jisheng decoction (DHJS) and its bioactive component acacetin on NPC fate and intervertebral disc integrity.

Key Innovation from the Reference Study

The central innovation of this work lies in the identification of the acacetin–MAPK1/HMOX1 regulatory axis as a critical modulator of the balance between mitophagy and pyroptosis in NPCs during IVDD. The study is the first to demonstrate that acacetin, a flavonoid identified as a circulating active compound of DHJS, directly binds and inhibits mitogen-activated protein kinase 1 (MAPK1). This inhibition lifts the negative regulation on heme oxygenase 1 (HMOX1), thereby enhancing mitophagy and suppressing pyroptosis—a form of inflammatory cell death closely implicated in disc degeneration. These mechanistic insights provide a new theoretical rationale for using traditional Chinese medicine (TCM) components in disease-modifying therapies for IVDD.

Methods and Experimental Design Insights

The research employed a comprehensive array of in vitro and in vivo methods to dissect the therapeutic effects and underlying mechanisms of DHJS and acacetin:

• Active compound identification: Ultra-high-performance liquid chromatography coupled with quadrupole-orbitrap high-resolution mass spectrometry (UHPLC-QE-MS) was used to identify acacetin as a major bioavailable compound in DHJS.
• Cellular assays: NPCs were treated with tert-butyl hydroperoxide (TBHP) to induce oxidative stress and pyroptosis, with or without DHJS/acacetin pretreatment. Key readouts included reactive oxygen species (ROS) detection, JC-1 mitochondrial membrane potential assay for mitophagy, and flow cytometry for cell death quantification.
• Molecular mechanism interrogation: Western blotting and network pharmacology predicted and validated the direct interaction between acacetin and MAPK1, and downstream regulation of HMOX1.
• In vivo validation: A rat model of IVDD was established to confirm the therapeutic efficacy of DHJS and acacetin, with outcome measures including histology (HE, safranin o-fast green staining), MRI, and immunodetection of mitophagy/pyroptosis markers.

Protocol Parameters

• DHJS administration: In vivo, administered at a dose and frequency established in preliminary dose-finding studies, beginning prior to or at the onset of IVDD induction in rats.
• Acacetin concentration: In vitro, NPCs treated with 10–50 μM acacetin, with optimal effects at 25 μM, as determined by dose–response viability and functional assays.
• Pyroptosis induction: TBHP applied at 100 μM for 24 h to trigger oxidative stress-mediated pyroptosis in cultured NPCs.
• Assessment endpoints: ROS measured using DCFH-DA assay; JC-1 dye for mitochondrial membrane potential; Western blotting for MAPK1, HMOX1, and mitophagy/pyroptosis markers.

Parameters above reflect both literature-backed values and practical workflow recommendations from the reference paper.

Core Findings and Why They Matter

The study established several key findings with important implications:

• DHJS and acacetin mitigate IVDD pathology: Both treatments significantly reduced disc degeneration in rat models, as evidenced by restored collagen architecture and proteoglycan content.
• Acacetin inhibits NPC pyroptosis: Acacetin treatment curtailed markers of pyroptosis (e.g., cleaved gasdermin D, IL-1β) in both in vitro NPC cultures and in vivo tissue.
• MAPK1–HMOX1 axis as a regulatory hub: Acacetin directly binds MAPK1, inhibiting its expression/activity. This relieves suppression of HMOX1, a cytoprotective enzyme, thereby enhancing mitophagy and cellular resilience to stress.
• Mitophagy–pyroptosis crosstalk: Enhanced mitophagy resulting from MAPK1 inhibition prevents mitochondrial dysfunction and excessive ROS accumulation, thereby reducing the initiation of pyroptosis. This axis is newly defined as central to the pathophysiology of IVDD (Yu et al., 2025).

These findings provide a mechanistic explanation for the disease-modifying effects of DHJS and acacetin, supporting further translational research into TCM-based or small-molecule targeted therapies for disc degeneration.

Comparison with Existing Internal Articles

While the present study focuses on the molecular and cellular mechanisms of IVDD and the specific role of mitophagy–pyroptosis crosstalk, existing internal articles provide complementary insights into the technical workflows necessary to study such mechanisms. For example, scenario-driven guides on Protein A/G Magnetic Beads (SKU K1305) detail best practices for antibody purification and immunoprecipitation, which are fundamental for validating protein-protein interactions and post-translational modifications—core to elucidating axes such as MAPK1/HMOX1. Similarly, expert-driven resources (see here) discuss optimizing immunoprecipitation and chromatin immunoprecipitation (Ch-IP) workflows for reproducibility and low background, supporting robust detection of protein–protein or protein–DNA interactions in models of inflammation and degeneration. These methodological frameworks enable researchers to translate mechanistic discoveries, such as those reported by Yu et al., into practical, high-confidence molecular assays for future studies.

Limitations and Transferability

Despite its comprehensive methodology, the reference study has limitations:

• Species-specific responses: Findings from rat models may not fully recapitulate human IVDD, and interspecies differences in NPC biology or TCM pharmacokinetics should be considered when extrapolating results.
• Complexity of TCM formulations: While acacetin was identified as a key DHJS component, the decoction contains multiple bioactive compounds with potential synergistic or antagonistic effects that were not fully dissected.
• Translational maturity: The MAPK1/HMOX1 axis represents a promising but preclinical target; more work is needed to validate its relevance in human tissues, and to assess safety/efficacy in clinical settings.
• Assay specificity: Although state-of-the-art biochemical and imaging tools were used, absolute specificity in detecting mitophagy and pyroptosis markers remains a technical challenge.

These factors underscore the need for further studies using patient-derived cells, more complex animal models, and advanced in situ or single-cell techniques to fully validate therapeutic strategies targeting this pathway.

Research Support Resources

For researchers aiming to investigate protein–protein interactions, post-translational modifications, or chromatin changes in the context of cell death and autophagy pathways, high-performance affinity reagents are essential. Techniques such as immunoprecipitation, co-immunoprecipitation, and Ch-IP benefit from magnetic beads with optimized specificity and low background. Protein A/G Magnetic Beads (SKU K1305) from APExBIO, composed of recombinant Protein A and Protein G domains covalently coupled to nanoscale magnetic particles, are designed to facilitate efficient antibody purification and protein interaction analysis in complex samples. Their minimized non-specific binding profile supports sensitive detection of signaling complexes, including those implicated in MAPK1/HMOX1 regulation. Incorporating such reagents into experimental workflows can enhance reproducibility and confidence in mechanistic studies of IVDD and related pathologies.